Physician profile
William E Norris
NPI 1801988811
$3,558.29
in general payments reported to CMS, 2019-2025
30 companies · $672 in 2025
The $672 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $501 · 2021: $104 · 2022: $720 · 2023: $673 · 2024: $888 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,233.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $959.08 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $362.93 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $308.14 | 2019-2024 | Xifaxan, Plenvu, Trulance |
| Boston Scientific Corporation | $258.53 | 2019-2024 | Exalt Model D |
| Janssen Biotech, INC. | $238.88 | 2019-2025 | Tremfya, Stelara, Simponi |
| Qol Medical, LLC | $190.28 | 2023-2024 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $169.09 | 2019-2023 | Linzess |
| Genzyme Corporation | $152.37 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $148.50 | 2019-2024 | Dificid |
| Madrigal Pharmaceuticals | $144.51 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $87.03 | 2019-2025 | |
| Amgen INC. | $51.69 | 2021-2022 | |
| Celgene Corporation | $46.25 | 2023 | Zeposia |
| Braintree Laboratories, INC. | $45.42 | 2022-2024 | Suflave, Sutab |
| Ipsen Biopharmaceuticals, INC | $36.75 | 2025 | Iqirvo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $36.32 | 2025 | Voquezna |
| Pentax of America, INC. | $35.67 | 2022 | |
| Nestle Healthcare Nutrition INC. | $35.43 | 2021-2022 | |
| Organon LLC | $35.01 | 2023-2024 | Hadlima, Renflexis |
| Astrazeneca Pharmaceuticals LP | $30.97 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $29.10 | 2023 | Zeposia |
| Daiichi Sankyo INC. | $24.72 | 2023 | Injectafer |
| Aimmune Therapeutics, INC. | $20.70 | 2025 | Zenpep |
| Taiho Oncology, INC. | $20.31 | 2019 | |
| Olympus America INC. | $18.48 | 2024 | Endoclot Phs, Gastrointestinal Videoscope |
| Regeneron Healthcare Solutions, INC. | $18.35 | 2024 | Dupixent |
| Fresenius Kabi USA, LLC | $14.61 | 2023 | Idacio |
| Mauna Kea Technologies, INC. | $14.02 | 2025 | |
| Allergan, INC. | $12.97 | 2019 | |
| Ferring Pharmaceuticals INC. | $12.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Norris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.